Carna Biosciences, Inc. has executed a Clinical Trial Agreement with The University of Texas MD Anderson Cancer Center for an investigator-initiated trial (IIT) using monzosertib (AS-0141). The trial targets relapsed or refractory AML and is a Phase 1b study evaluating the safety, tolerability, and efficacy of monzosertib as monotherapy and in a three-drug combination with AZA\/VEN. The company will supply monzosertib and cover trial-related costs. There is no impact on consolidated earnings forecasts for the fiscal year ending December 2026.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4572","jir_company_name":"Carna Biosciences, Inc.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-10-05","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4572-20261005-01.pdf","jir_short_summary":"Carna Biosciences, Inc. has executed a Clinical Trial Agreement with The University of Texas MD Anderson Cancer Center for an investigator-initiated trial (IIT) using monzosertib (AS-0141). The trial targets relapsed or refractory AML and is a Phase 1b study evaluating the safety, tolerability, and efficacy of monzosertib as monotherapy and in a three-drug combination with AZA\/VEN. The company will supply monzosertib and cover trial-related costs. There is no impact on consolidated earnings forecasts for the fiscal year ending December 2026.","jir_summary":"### Business \/ Partnership Highlights\nCarna Biosciences, Inc. has executed a Clinical Trial Agreement with The University of Texas MD Anderson Cancer Center for an investigator-initiated trial (IIT) targeting monzosertib (AS-0141). This Phase 1b trial will enroll patients with relapsed or refractory AML to evaluate the safety, tolerability, and efficacy of monzosertib as a single agent and in a three-drug combination with azacitidine\/venetoclax (AZA\/VEN). The company will supply the necessary monzosertib and bear trial-related costs. The principal investigator is Dr. Abhishek Maiti, and the trial will proceed under the policies of MD Anderson Cancer Center.\n\n### Impact for Shareholders & Outlook\nThe trial aims to develop new therapeutic options and accumulate important data to improve treatment outcomes in the AML field. There is no impact on consolidated earnings forecasts for the fiscal year ending December 2026. Registration updates on ClinicalTrials.gov will be made in accordance with MD Anderson Cancer Center policy, and the company will not normally provide separate notifications.","jir_financial_highlights":"Impact amount \/ Financial indicator: Unknown (Unknown)\nExchange rate (JPY\/USD): 0.00634236062662523 (Acquisition date: 2026-10-02)\nImpact on consolidated earnings forecast: Unknown (Unknown)","jir_category":"","jir_hashtags":"#CarnaBiosciences, #Pharmaceuticals, #ClinicalTrial, #Partnership","jir_key_figures":"Supply of monzosertib and coverage of trial-related costs (specific amount unknown)\nExchange information: JPY\/USD 0.00634236062662523 (acquisition date 2026-10-02)\nImpact on consolidated earnings forecast is \"Unknown\" but stated as no impact (fiscal year ending December 2026)","jir_meta_title":"Carna Biosciences, Inc. Executes Clinical Trial Agreement with MD Anderson for monzosertib | October 2026","jir_meta_description":"Carna Biosciences, Inc. has entered a CTA with The University of Texas MD Anderson Cancer Center for an investigator-initiated Phase 1b trial of monzosertib in AML patients to evaluate safety, tolerability, and efficacy. No impact on fiscal 2026 consolidated forecasts.","jir_og_title":"Carna Biosciences, Inc. Executes Clinical Trial Agreement with MD Anderson for monzosertib","jir_og_description":"Carna Biosciences, Inc. has executed a CTA with MD Anderson Cancer Center for a clinical trial of monzosertib targeting AML. The company will bear trial costs; financial impact is currently unknown.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59427,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"general_ir","footnotes":""},"sector":[],"importance":[],"class_list":["post-127550","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n